Loading…
Ironwood Pharmaceuticals, Inc. is projected to decline to $3.63 by 2027, a -2% move from its current price of $3.71. IRWD is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean strong sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 5/28/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| May 29 | $3.56 | $3.71 | $3.87 | -0.03% |
| May 30 | $3.49 | $3.71 | $3.93 | -0.06% |
| May 31 | $3.45 | $3.71 | $3.99 | -0.10% |
| Jun 1 | $3.41 | $3.71 | $4.03 | -0.13% |
| Jun 2 | $3.37 | $3.70 | $4.07 | -0.16% |
| Jun 3 | $3.34 | $3.70 | $4.10 | -0.19% |
| Jun 4 | $3.31 | $3.70 | $4.14 | -0.22% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $3.31 | $3.70 | $4.14 | -0.22% |
| Week 2 | $3.16 | $3.69 | $4.32 | -0.45% |
| Week 3 | $3.04 | $3.69 | $4.46 | -0.67% |
| Week 4 | $2.95 | $3.68 | $4.59 | -0.89% |
| Week 5 | $2.86 | $3.67 | $4.70 | -1.12% |
| Week 6 | $2.79 | $3.66 | $4.80 | -1.34% |
| Week 7 | $2.72 | $3.65 | $4.90 | -1.56% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Ironwood Pharmaceuticals, Inc. is a biotechnology company focused on the development and commercialization of therapies for gastrointestinal and rare diseases in the United States and internationally.
It sells linaclotide, a guanylate cyclase type-C (GC-C) agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation, as well as for pediatric patients suffering from functional constipation under the LINZESS and CONSTELLA names.
The company is developing IW-3300, a GC-C agonist for the treatment of visceral pain conditions, including interstitial cystitis/bladder pain syndrome and endometriosis; and Apraglutide, a synthetic peptide long-acting analog of glucagon-like peptide-2 for short bowel syndrome patients dependent on parenteral support, as well as for acute graft versus host disease. It has strategic partnerships with AbbVie Inc., AstraZeneca AB, and Astellas Pharma Inc. for the development and commercialization of linaclotide.
The company was formerly known as Microbia, Inc. and changed its name to Ironwood Pharmaceuticals, Inc. in April 2008. Ironwood Pharmaceuticals, Inc. was incorporated in 1998 and is headquartered in Boston, Massachusetts.
Ironwood Pharmaceuticals, Inc. (IRWD) is a biotechnology company focused on GI and rare-disease therapies, with linaclotide marketed for adults and children under LINZESS and CONSTELLA. Current indicators show a price of $3.92 with a market cap of $645.28M, and a rank of 2848 by size.
The near-term outlook shows a mixed path, while longer-term forecasts imply a meaningful upside with higher average prices in later years. The 2030 average is projected at $6.23, rising further to $10.75 by 2040 and to $22.74 by 2050, with substantial upside in the 2030s and 2040s. Investors should note that these figures are estimates and not guarantees, and year-by-year volatility is possible.
A major floor 27.7% below — a decisive break under it would weaken the trend.
The nearest floor, 5.7% below — buyers have tended to step in here.
The nearest ceiling, 30.2% above — a clean break opens room to run.
A major ceiling 45.3% above — clearing it would confirm fresh momentum.
Key IRWD support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of IRWD market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $3.86 | Sell | $3.81 | Sell |
| MA 10 | $3.74 | Sell | $3.85 | Sell |
| MA 20 | $4.04 | Sell | $3.92 | Sell |
| MA 50 | $3.81 | Sell | $3.91 | Sell |
| MA 100 | $4.06 | Sell | $3.75 | Sell |
| MA 200 | $3.08 | Buy | $3.36 | Buy |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 44.24 | Neutral |
| Stoch RSI (14) | 42.98 | Neutral |
| CCI (20) | -73.27 | Neutral |
| Williams %R (14) | -70.83 | Info |
| MACD (12,26,9) | -0.04 | Sell |
| ROC (12) | -12.09 | Sell |
| Bollinger %B (20,2) | 0.27 | Neutral |
| Stochastic %K (14) | 29.17 | Neutral |
| TRIX (15) | -0.05 | Sell |
| Awesome (5,34) | -0.19 | Sell |
| Ultimate (7,14,28) | 46.08 | Neutral |
| Momentum (10) | -0.38 | Sell |
| Aroon Osc (25) | -32.00 | Sell |
| Hull MA (9) | 3.92 | Sell |
| ADX (14) | 12.64 | Neutral |
| ATR (14) | 0.15 | Info |
The 30-day technical picture is neutral overall. RSI14 is 50, with the 50-day simple moving average at $3.80 and the 200-day simple moving average at $3.05.
Near-term support is seen at $3.50, with resistance at $4.83. The stock has traded in a 30-day range of $2.95 to $5.21, indicating room for movement within a moderate band over the coming weeks.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $3.04 | $3.71 | $4.46 | 0% | Neutral | |
| $2.73 | $3.63 | $5.19 | -2% | Neutral | |
| $2.88 | $4.00 | $6.01 | +8% | Neutral | |
| $3.42 | $4.94 | $7.73 | +33% | Bullish | |
| $3.84 | $5.73 | $9.27 | +55% | Bullish | |
| $3.84 | $5.92 | $9.85 | +60% | Bullish | |
| $3.94 | $6.25 | $10.68 | +69% | Bullish | |
| $3.52 | $5.75 | $10.05 | +55% | Bullish | |
| $3.46 | $5.80 | $10.35 | +56% | Bullish | |
| $4.59 | $7.91 | $14.40 | +113% | Bullish | |
| $4.99 | $9.71 | $19.17 | +162% | Bullish | |
| $9.24 | $20.54 | $45.55 | +454% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| May 2026 | $3.04 | $3.71 | $4.37 | +0.00% |
| June 2026 | $3.00 | $3.57 | $4.37 | -3.84% |
| July 2026 | $2.99 | $3.60 | $4.50 | +0.99% |
| August 2026 | $2.99 | $3.64 | $4.62 | +0.94% |
| September 2026 | $2.79 | $3.42 | $4.40 | -5.85% |
| October 2026 | $2.64 | $3.26 | $4.24 | -4.77% |
| November 2026 | $2.69 | $3.35 | $4.40 | +2.72% |
| December 2026 | $2.68 | $3.36 | $4.46 | +0.40% |
Click any year to see its month-by-month IRWD forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
By 2026, IRWD could reach as high as $4.46, with a base case around $3.71 and support toward $3.04 — roughly 0% from $3.71. A consolidation phase looks the most probable path here.
Expect IRWD to range from $2.73 to $5.19 through 2027. The $3.63 average target implies a -2% move from current prices. That is -2% versus the projected 2026 average. Price action looks broadly range-bound.
The IRWD price prediction for 2028 points to an average of $4.00 (low $2.88, high $6.01) — a potential gain of +8% on today's $3.71. A consolidation phase looks the most probable path here.
In 2029, IRWD is projected to trade between $3.42 and $7.73, averaging $4.94 — a potential gain of +33% from today's $3.71. That is up +23% on the projected 2028 average. Momentum favours further upside here.
Ironwood Pharmaceuticals, Inc.'s 2030 outlook centres on $5.73, within a $3.84 to $9.27 range. That is up +16% on the projected 2029 average. That marks a +55% change versus current levels. Buyers look set to stay in control over this stretch.
By 2031, IRWD could reach as high as $9.85, with a base case around $5.92 and support toward $3.84 — roughly +60% from $3.71. Momentum favours further upside here.
Expect IRWD to range from $3.94 to $10.68 through 2032. The $6.25 average target implies a +69% move from current prices. That is up +6% on the projected 2031 average. Buyers look set to stay in control over this stretch.
The IRWD price prediction for 2033 points to an average of $5.75 (low $3.52, high $10.05) — a potential gain of +55% on today's $3.71. Momentum favours further upside here.
In 2034, IRWD is projected to trade between $3.46 and $10.35, averaging $5.80 — a potential gain of +56% from today's $3.71. That is up +1% on the projected 2033 average. Buyers look set to stay in control over this stretch.
Ironwood Pharmaceuticals, Inc.'s 2035 outlook centres on $7.91, within a $4.59 to $14.40 range. That is up +36% on the projected 2034 average. That marks a +113% change versus current levels. Momentum favours further upside here.
By 2040, IRWD could reach as high as $19.17, with a base case around $9.71 and support toward $4.99 — roughly +162% from $3.71. Buyers look set to stay in control over this stretch.
Expect IRWD to range from $9.24 to $45.55 through 2050. The $20.54 average target implies a +454% move from current prices. That is up +112% on the projected 2040 average. Momentum favours further upside here.
Investing $1,000 in IRWD today (≈ 269.541779 IRWD) could be worth
$5,535.7
+$4,535.7 (+454%) by 2050 · US Dollar
Based on the average projected IRWD price of $20.54 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in IRWDwould be worth at today's price.
$1,000 invested in IRWD on May 27, 2025 (≈ 1,612.903213 IRWD) would be worth
$5,983.87
+$4,983.87 (+498.4%) today · 5.98× · US Dollar
Based on a IRWD entry price of $0.62 vs. today's $3.71.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $3.92 | $946.43 | -5.4% |
| 1 month ago | $4.04 | $918.32 | -8.2% |
| 3 months ago | $3.66 | $1,013.66 | +1.4% |
| 6 months ago | $3.5 | $1,060 | +6.0% |
| 1 year ago | $0.62 | $5,983.87 | +498.4% |
| All time (5.0y) ago | $11.56 | $320.93 | -67.9% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our IRWD forecast.
Our base-case forecast reaches $7.40 around 2035.
Implied market cap at $7.40: $1.22B
The multi-year forecast portrays a shift from neutral to bullish sentiment as price forecasts rise across the period. For 2026 the average is $3.92 and the year is neutral. In 2027 the average is $3.85 with a slight negative ROI of -1.7%.
From 2028 onward, the path turns bullish. The 2028 average is $4.34 (ROI 10.7%), the 2029 average $5.31 (ROI 35.5%), and the 2030 average $6.23 (ROI 58.9%). The 2031–2032 outlooks show averages of $6.48 and $6.73 with ROIs of 65.4% and 71.6%, respectively.
The forecast continues higher through 2033–2035, with 2033 average $6.23 (ROI 59%), 2034 average $6.39 (ROI 62.9%), and 2035 average $8.72 (ROI 122.5%). By 2040 the average is projected at $10.75 with ROI of 174.2%, and by 2050 the average could reach $22.74 with ROI of 480.1%.
These are estimates and not guarantees. The later years show substantial upside potential, but investors should be mindful of the inherent uncertainty in long-range forecasts.
Tap a question to reveal the answer.
Avg: $6.23; Min: $4.13; Max: $10.17; ROI: 58.9%; Sentiment: BULLISH.
The outlook shifts from Neutral in 2026–2027 to Bullish from 2029 onward, with the average price rising to $6.23 by 2030, $10.75 by 2040, and $22.74 by 2050. Notably, 2027 shows a negative ROI of -1.7%, indicating some downside risk in the near term.
Yes. The 2030 max is $10.17, while the 2030 average is $6.23 and the ROI is 58.9%.
RSI 14 is 50, SMA50 is $3.80, SMA200 is $3.05. Support is $3.50 and resistance is $4.83, with a 30-day price range of $2.95 to $5.21.
Current price: $3.92. Market cap: $645.28M. Rank: 2848.
Ironwood Pharmaceuticals, Inc. Community Discussion
0Share your Ironwood Pharmaceuticals, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.